Abstract
Background: Understanding the interplay between novel molecular drivers is critical to optimize biomarker-driven clinical studies for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). This study used real world data, in vitro signaling, phenotypic assays and xenograft models to investigate HRAS overexpression, PIK3CA mutation and amplification as targets for combination therapy with tipifarnib, a farnesyl transferase inhibitor, and alpelisib, a PI3Ka inhibitor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
